In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how clinical trial sites and sponsors are responding to funding constraints by turning to telemedicine, cost-containment strategies, and increased reliance on industry-sponsored research.
In a recent video interview with Applied Clinical Trials, Kyle McAllister, co-founder, CEO, Trially, discussed the impact of funding cuts on underrepresented populations in medical research, emphasizing the importance of diversity-focused research. He highlighted the challenges created by budget cuts, particularly in patient recruitment and retention, due to reduced support staff. McAllister noted that artificial intelligence (AI) and new technologies like telemedicine are crucial for addressing these challenges by automating tasks and improving efficiency. He provided examples of AI's success in reducing chart review time and increasing patient enrollment in studies.
ACT: How are clinical trial sites and sponsors adapting to these constraints?
McAllister: Ultimately, they're doing more with less, like I said before, they're resource constrained, and they're doing more with less, which looks like a lot of things, but it's leveraging new technologies like telemedicine or other tools that could decrease the cost of the actual care being provided, so cost containment measures, using remote monitoring tools, using teams that didn't previously work together across multiple types of studies or departments. We've seen sites turning more towards industry sponsored trials to drive more revenue and ultimately cover some of the research they're doing that was NIH and other government funded research, essentially using pharma money to keep the lights on and keep things moving forward. Not all that's terrible, like the idea of moving towards more efficiency and finding ways to drive more revenue to keep things more sustainable, there's some positive things in that, but I think the one of the big potential conflicts is it creates is a lot of the shift towards more industry sponsored research means the institutional priorities being shifted away from public interest focused research. Like I said, there's some pro in that, but there's also some real conflict and concern.
I think the brutal reality for a lot of sites is they're being forced to adapt in ways that aren't great, like they're having to cut staff, they're having to close departments, they're having to close research programs. I think there is a lot of, I'll say, research capacity that disappears with that, that it's going to take time to grow back. There's just research capacity that can't be covered, and we're in an age where it's easier and easier to find new molecules, find new things to do research on, and this infrastructure that was there to actually run that research is being whittled back. Sites are doing heroic work out there, but I worry that heroism isn't a sustainable staffing model.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.